

## Guidelines on ACS-NSTE (TF21) - Task Force Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Agewall Stefan	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Platelet inhibition
Bassand Jean-Pierre	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Glaxo Smith Kline : fondaparinux - Lilly : prasugrel - Astra Zeneca : ticagrelor
Bax Jeroen	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Heart.org : Education - Astra Zeneca : Farma - Servier : Farma - Philips : Imaging - GE Healthcare : Imaging - Lantheus : Imaging - Boston Scientific : Pacing - Medtronic : Pacing - St Jude Medical : Pacing - Biotronik : Pacing - Impulse Dynamics : Pacing D - Research funding (departmental or institutional). - Servier : Farma - Edwards Lifesciences : Heart Valves - GE Healthcare : Imaging - Lantheus : Imaging - Boston Scientific : Pacing - Medtronic : Pacing - St Jude Medical : Pacing

## Guidelines on ACS-NSTE (TF21) - Task Force Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Bax Jeroen	Yes	- Biotronik : Pacing
Boersma Eric	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : coronary artery disease
Bueno Hector	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : Aspirin - Merck, Schering Plough : None - Daiichi Sankyo : Prasugrel - Eli Lilly : Prasugrel - Astra Zeneca : Ticagrelor
Caso Pio	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Consorzio formazione medica : lessons C - Receipt of royalties for intellectual property. - piccin nuova libreria spa : book
Dudek Dariusz	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : speaker fee, advisory boards, investigator. - Boston Scientific : speaker fee, advisory boards, investigator. - Eli Lilly : speaker fee, advisory boards, investigator. - Pfizer : speaker fee, advisory boards, investigator. - Sanofi Aventis : speaker fee, advisory boards, investigator. - Siemens Healthcare : speaker fee, advisory boards, investigator. - GlaxoSmithKline : speaker fee, advisory boards, investigator. - Bayer Healthcare : speaker fee, advisory boards, investigator. - Cook Medical : speaker fee, advisory boards, investigator. - Medicines Company : speaker fee, advisory boards, investigator. - Nycomed : speaker fee, advisory boards, investigator. - Bristol Myers Squibb : speaker fee, advisory boards, investigator. - MSD : speaker fee, advisory boards, investigator.

## Guidelines on ACS-NSTE (TF21) - Task Force Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Dudek Dariusz	Yes	<ul style="list-style-type: none"> <li>- Balton : speaker fee, advisory boards, investigator.</li> <li>- Cordis : speaker fee, advisory boards, investigator.</li> <li>- Biotronic : speaker fee, advisory boards, investigator.</li> <li>- Solvay : speaker fee, advisory boards, investigator.</li> <li>- BBraun : speaker fee, advisory boards, investigator.</li> <li>- EuroCor : speaker fee, advisory boards, investigator.</li> <li>- INvatec : speaker fee, advisory boards, investigator.</li> <li>- Medtor : speaker fee, advisory boards, investigator.</li> <li>- Promed : speaker fee, advisory boards, investigator.</li> <li>- Therumo : speaker fee, advisory boards, investigator.</li> <li>- Tyco : speaker fee, advisory boards, investigator.</li> <li>E - Research funding (personal).</li> <li>- Abbott : speaker fee, advisory boards, investigator.</li> <li>- Adamed : speaker fee, advisory boards, investigator.</li> <li>- Astra Zeneca : speaker fee, advisory boards, investigator.</li> <li>- Boehringer-Ingelheim : speaker fee, advisory boards, investigator.</li> <li>- Boston Scientific : speaker fee, advisory boards, investigator.</li> <li>- Eli Lilly : speaker fee, advisory boards, investigator.</li> <li>- Medtronic : speaker fee, advisory boards, investigator.</li> <li>- Pfizer : speaker fee, advisory boards, investigator.</li> <li>- Biotronik : speaker fee, advisory boards, investigator.</li> <li>- Terumo Inc : speaker fee, advisory boards, investigator.</li> <li>- Sanofi Aventis : speaker fee, advisory boards, investigator.</li> <li>- Siemens Healthcare : speaker fee, advisory boards, investigator.</li> <li>- GlaxoSmithKline : speaker fee, advisory boards, investigator.</li> </ul>

## Guidelines on ACS-NSTE (TF21) - Task Force Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Dudek Dariusz	Yes	<ul style="list-style-type: none"> <li>- Bayer Healthcare : speaker fee, advisory boards, investigator.</li> <li>- Cook Medical : speaker fee, advisory boards, investigator.</li> <li>- Nycomed : speaker fee, advisory boards, investigator.</li> <li>- MSD : speaker fee, advisory boards, investigator.</li> <li>- Balton : speaker fee, advisory boards, investigator.</li> <li>- Cordis : speaker fee, advisory boards, investigator.</li> <li>- Solvay : speaker fee, advisory boards, investigator.</li> <li>- BBraun : speaker fee, advisory boards, investigator.</li> <li>- EuroCor : speaker fee, advisory boards, investigator.</li> <li>- INVatec : speaker fee, advisory boards, investigator.</li> <li>- Promed : speaker fee, advisory boards, investigator.</li> <li>- Tyco : speaker fee, advisory boards, investigator.</li> <li>- Biomatrix : speaker fee, advisory boards, investigator.</li> <li>- Mediciine Company : speaker fee, advisory boards, investigator.</li> </ul>
Gielen Stephan	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Genzyme : Lecture on genetic cardiac diseases incl. M. Fabry, 1000 € honorarium</li> <li>- Astra zeneca, boheringer, menarini : Product-independent cardiology case workshop twice a year, honorarium 1.100 € per event</li> </ul>
Hamm Christian	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck : drugs</li> <li>- Pfizer : drugs</li> <li>- Sanofi-Aventis : drugs</li> <li>- The Medicines Company : drugs</li> <li>- Menarini : drugs</li> <li>- Daiichi-Sankyo : drugs</li> <li>- Berlin Chemie AG : drugs</li> </ul>

## Guidelines on ACS-NSTE (TF21) - Task Force Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Hamm Christian	Yes	<ul style="list-style-type: none"> <li>- Heart.org : drugs</li> <li>- Boehringer Ingelheim - Ingelheim; Daiichi-Sankyo/Eli Lilly; Nycomed Pharma : drugs</li> <li>- Takeda Pharmaceuticals : drugs</li> <li>- Glaxo Smith Kline : drugs</li> <li>- Astra Zeneca, Bayer AG, Boehringer-Ingelheim, Daiichi-Sankyo, MSD, Novartis, Pfizer, Sanofi-Aventis, Servier : drugs</li> <li>- BRAHMS GmbH : markers</li> <li>- Siemens Healthcare : MRI</li> <li>- Boston Scientific : PCI</li> <li>- Cordis and Medtronic : PCI</li> </ul>
Huber Kurt	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer - speakers fees : atorvastatin</li> <li>- The Medicines Company - speakers fees : bivalirudin; cangrelor</li> <li>- BRAHMS GmbH - speakers fees : copeptin assay</li> <li>- Boehringer Ingelheim - speakres fees; advisory board fees (dabigatran) : dabigatran</li> <li>- Boston Scientific - speakres fees : none</li> <li>- Biotronik - speakers fees : none</li> <li>- Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : prasugrel; abciximab</li> <li>- Bayer - speaker fees; advisory board fees (rivaroxaban) : rivaroxaban</li> <li>- Astra Zeneca - speakers fees; advisory board fees (ticagrelor) : ticagrelor; rosuvastatin</li> </ul>
Ohman E Magnus	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Liposcience : Diagnostic tests</li> <li>- WebMD : Online health information provider</li> <li>- Astra Zeneca : Pharmaceuticals</li> <li>- Boehringer-Ingelheim : Pharmaceuticals</li> <li>- The Medicines Company : Pharmaceuticals</li> </ul>

## Guidelines on ACS-NSTE (TF21) - Task Force Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Ohman E Magnus	Yes	<ul style="list-style-type: none"> <li>- Sanofi Aventis : Pharmaceuticals</li> <li>- Bristol Myers Squibb : Pharmaceuticals</li> <li>- Merck Sharp &amp; Dohme : Pharmaceuticals</li> <li>- Gilead Sciences : Pharmaceuticals</li> <li>- Pozen, Inc. : Pharmaceuticals</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Pharmaceuticals</li> <li>- Eli Lilly : Pharmaceuticals</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Maquet : Medical technology/products</li> <li>- Daiichi Sankyo : Pharmaceuticals</li> <li>- Eli Lilly : Pharmaceuticals</li> </ul>
Petrie Mark	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Roche : diabetes</li> <li>- GSK : diabetes</li> <li>- Astellas : diabetes</li> <li>- Servier : heart failure</li> </ul>
Sonntag Frank	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : CAD</li> <li>- Sanofii-Aventis : CAD</li> <li>- Bayer Healthcare : CAD</li> <li>- Merck Sharp &amp; Dome : CAD</li> <li>- Boehringer Ingelheim - : CAD</li> <li>- Astra Zeneca : CAD,Plateletaggregationinhibitor</li> </ul>
Sousa Uva Miguel	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : TAVI</li> </ul>

## Guidelines on ACS-NSTE (TF21) - Task Force Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Sousa Uva Miguel	Yes	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Lilly : Antiplatelet agent
Storey Robert Frederick	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - The Medicines Company : Cangrelor - Sanofi Aventis : Clopidogrel - Bristol Myers Squibb : Clopidogrel - Novartis : Elinogrel - GlaxoSmithKline : Fondaparinux - Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : Prasugrel - Astra Zeneca : Ticagrelor - Merck : Vorapaxar  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Ticagrelor - Accumetrics : VerifyNow  D - Research funding (departmental or institutional). - Daiichi Sankyo : Prasugrel - Eli Lilly : Prasugrel - Astra Zeneca : Ticagrelor - Merck : Vorapaxar
Wijns William	Yes	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : device - Edwards Lifesciences : device - Terumo Inc : device - Cordis : device - Orbus Neich : device - Astra Zeneca : drug

## Guidelines on ACS-NSTE (TF21) - TF Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Wijns William	Yes	<ul style="list-style-type: none"> <li>- Eli Lilly : drug</li> <li>- GlaxoSmithKline : drug</li> <li>- Bristol Myers Squibb : drug</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Cardio3 Biosciences : cell therapy</li> <li>- Boston Scientific : device</li> <li>- Medtronic : device</li> <li>- St Jude Medical : device</li> <li>- Abbott Laboratories : device</li> <li>- Biotronic : device</li> <li>- Therabel : drug</li> <li>- Ablynx : nano antibodies</li> </ul> </li> </ul>
Zahger Doron	Yes	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Sanofi Aventis : Dronedarone</li> <li>- Pfizer : lipitor</li> <li>- Eli Lilly : prasugrel</li> <li>- Astra zeneca, boheringer, menarini : Ticagrelor</li> </ul> </li> </ul>



## Guidelines on ACS-NSTE (TF21) - Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Achenbach Stephan	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : CT</li> <li>- Servier : Imaging</li> <li>- Guerbet : Imaging</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : Imaging</li> <li>- Bayer Healthcare : Imaging</li> </ul>
Badimon Lina	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : cardiovascular</li> <li>- Menarini : cardiovascular</li> <li>- Esteve : Cardiovascular</li> </ul>
Bertrand Michel	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Lilly : Anticoagulants</li> <li>- Servier International : Antihypertensive drugs. Antiischemic drugs</li> </ul>
Botker Hans Erik	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca - speaker fee : Hyperlipidemia, angina pectoris</li> </ul>
Collet Jean-Philippe	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : apixaban</li> <li>- Nycomed : aspirin</li> <li>- Sanofi Aventis : clopidogrel</li> <li>- Roche Diagnostics : hypersensitive troponin</li> <li>- Astra Zeneca : prasugrel</li> <li>- Eli Lilly : prasugrel</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Sanofi-Aventis : clopidogrel</li> <li>- Cordis and Medtronic : platelet function testing</li> </ul>
Crea Filippo	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer - speakers fees : Atorvastatin</li> </ul>

## Guidelines on ACS-NSTE (TF21) - Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Crea Filippo	Yes	<ul style="list-style-type: none"> <li>- Boehringer Ingelheim-Advisory Board : Dabigatran</li> <li>- GSK : Darapladip</li> <li>- Sanofi Aventis - speaker fee : Prasugrel</li> <li>- Astra Zeneca - speaker fee : Rosuvastatin</li> <li>- Chiesi - speaker fees : Rosuvastatin</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Pfizer : Atorvastatin</li> <li>- Sanofi Aventis : Prasugrel</li> <li>- Chiesi - speaker fees : Rosuvastatin</li> </ul>
Danchin Nicolas	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : antianginal agents</li> <li>- The Medicines Company : Antithrombotic agents</li> <li>- BMS/Pfizer : Antithrombotic agents</li> <li>- Boehringer Ingelheim : Antithrombotic agents</li> <li>- Daiichi Sankyo, Eli-Lilly : Antithrombotic agents</li> <li>- Sanofi-Aventis : antithrombotic agents, antiarrhythmic agents</li> <li>- Astra-Zeneca : Antithrombotic agents, statins</li> <li>- Novo-Nordisk : Diabetes</li> <li>- Pierre Fabre : Omega 3</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Merck : Myocardial infarction</li> <li>- Sanofi-Aventis : Myocardial infarction</li> <li>- The Medicines Company : Myocardial infarction</li> <li>- GSK : Myocardial infarction</li> <li>- Astra-Zeneca : Myocardial infarction</li> <li>- Daiichi-Sankyo Eli Lilly : Myocardial infarction</li> </ul>

## Guidelines on ACS-NSTE (TF21) - Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Falk Erling	No	
Goudevenos John A	No	
Gulba Dietrich Cl	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- The Medicines Company : Bivalirudin</li> <li>- Boehringer-Ingelheim : Dabigatran, rt-PA, TNK-tPA</li> <li>- Sanofi Aventis : Enoxaparin</li> <li>- Daiichi Sankyo : Prasugrel</li> <li>- Eli Lilly : Prasugrel, abciximab</li> <li>- Bayer Healthcare : Rivaroxaban</li> <li>- Astra Zeneca : Ticagrelor</li> </ul>
Hambrecht Rainer	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Berlin Chemie : ranolazine</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- pohl boskamp : nitrates</li> </ul>
Herrmann Joerg	No	
Kastrati Adnan	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott - lecture fees : DES</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet</li> <li>- Lilly : Antiplatelet</li> <li>- Biosensors : DES</li> <li>- Cordis : DES</li> <li>- Biotronic : DES</li> </ul>
Kjeldsen Keld Per	No	
Kristensen Steen Dalby	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Antithrombotics</li> <li>- Eli Lilly : Antithrombotics</li> </ul>

## Guidelines on ACS-NSTE (TF21) - Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Kristensen Steen Dalby	Yes	<ul style="list-style-type: none"> <li>- Merck : Antithrombotics</li> <li>- The Medicines Company : Antithrombotics</li> <li>- AstraZeneca : Antithrombotics</li> </ul>
Lancellotti Patrizio	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- ,astra zeneca, boheringer, menarini : pradaxa, belsar, crestor</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : tracleer</li> </ul>
Mehilli Julinda	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo - speaker fee : Antithrombotic drugs</li> <li>- Abbott - lecture fees : Stents</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Unrestricted grant for clinical studies</li> <li>- Terumo : Unrestricted grant for clinical studies</li> </ul>
Merkely Bela	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott, Biotronik, Boston Sci, Medtronic, Sanofi-Aventis, Servier, St. Jude : CRT implantation, ICD programing, education program, dronaderone, ivabradine</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott, Johnson &amp; Johnson, Medtronic, : Xience V stent, education program</li> </ul>
Montalescot Gilles	Yes	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca - consulting or lecture fees : xy</li> <li>- Bayer - consulting or lecture fees : xy</li> <li>- Boehringer Ingelheim - consulting or lecture fees : xy</li> <li>- Cardiovascular Research Foundation - consulting or lecture fees : xy</li> <li>- Cleveland Clinic Research Foundation - consulting or lecture fees : xy</li> <li>- Daiichi Sankyo - consulting or lecture fees : xy</li> <li>- Duke Institute - consulting or lecture fees : xy</li> <li>- Eli Lilly - consulting or lecture fees : xy</li> </ul>

## Guidelines on ACS-NSTE (TF21) - Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Montalescot Gilles	Yes	<ul style="list-style-type: none"> <li>- Europa - consulting or lecture fees : xy</li> <li>- Lead-Up - consulting or lecture fees : xy</li> <li>- GSK - consulting or lecture fees : xy</li> <li>- Institut de Cardiologie de Montreal - consulting or lecture fees : xy</li> <li>- Menarini - consulting or lecture fees : xy</li> <li>- Nanospheres - consulting or lecture fees : xy</li> <li>- Novartis - consulting or lecture fees : xy</li> <li>- Pfizer - consulting or lecture fees : xy</li> <li>- Portola - consulting or lecture fees : xy</li> <li>- Sanofi Aventis - consulting or lecture fees : xy</li> <li>- The Medicines Company - consulting or lecture fees : xy</li> <li>- TIMI study group - consulting or lecture fees : xy</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : xy</li> <li>- BMS : xy</li> <li>- Boston Scientific : xy</li> <li>- Eli Lilly : xy</li> <li>- Medtronic : xy</li> <li>- Pfizer : xy</li> <li>- Servier : xy</li> <li>- Sanofi Aventis : xy</li> <li>- Abbott Vascular : xy</li> <li>- Cordis : xy</li> <li>- Fédération Française de Cardiologie : xy</li> <li>- Fondation de France : xy</li> </ul>

## Guidelines on ACS-NSTE (TF21) - Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Montalescot Gilles	Yes	<ul style="list-style-type: none"> <li>- Guerbet Medical : xy</li> <li>- INSERM : xy</li> <li>- ITC Edison : xy</li> <li>- Société Française de Cardiologie : xy</li> <li>- Stago : xy</li> </ul>
Neumann Franz Josef	Yes	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : devices</li> <li>- Medtronic : devices</li> <li>- Cordis : devices</li> <li>- Biotronic : devices</li> <li>- Astra Zeneca : drugs</li> <li>- The Medicines Company : drugs</li> <li>- Lilly : drugs</li> <li>- Siemens Healthcare : equipment</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Boston Scientific : devices</li> <li>- Cordis : devices</li> <li>- Metronic : devices</li> <li>- Lilly : drugs</li> </ul>
Neyses Ludwig	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier - speaker fees; investigator fees : Ivabradine</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : Diagnostic use of metabolomics</li> </ul>
Perk Joep	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca - speaker fees : None specific</li> </ul>

## Guidelines on ACS-NSTE (TF21) - Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Perk Joep	Yes	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : None specific
Pfisterer Matthias	No	
Roffi Marco	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : Antiplatelet therapy D - Research funding (departmental or institutional). - Abbott : devices - Boston Scientific : devices - Cordis and Medtronic : devices - Biotronik : devices
Romeo Francesco	No	
Ruda Mikhail Ya	No	
Swahn Eva	Yes	D - Research funding (departmental or institutional). - Schering-Plough : Phase III study (TRACER)
Tavares Aguiar Carlos Manuel	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp & Dohme - speaker fees : Niacin/Laropiprant - Menarini - speaker fees : Olmesartan - Servier - speaker fees; investigator fees : Perindopril/Indapamide, Ivabradine - Lilly - consultancy fees : Prasugrel - Bayer - speaker fees; advisory board fees (rivaroxaban) : Rivaroxaban, Nifedipine, Telmisartan, Aspirin - Astra Zeneca - speaker fees : Rosuvastatin - Boehringer Ingelheim - speaker fees : Telmisartan - Bial Portela - speaker fees : Valsartan/Amlodipine
Valgimigli Marco	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - The Medicines Company : bivalirudin - Terumo : Interventional cardiology

## Guidelines on ACS-NSTE (TF21) - Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Valgimigli Marco	Yes	<ul style="list-style-type: none"> <li>- Abbott Laboratories : ngal</li> <li>- Accumetrics : Platlet Function Assay</li> <li>- Roche Pharma : PPAR alpha/gamma</li> <li>- Medtronic : stent</li> <li>- Abbott Vascular : stent</li> <li>- Cordis : stent</li> <li>- CID : stent</li> <li>- Astra Zeneca - consulting or lecture fees : ticagrelor</li> <li>- Chiesi Pharma : tirofiban</li> <li>- Iroko Cardio : Tirofiban</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott Laboratories : ngal</li> </ul>
Vrints Christian Joseph Marie	Yes	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : pharma</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : interventional cardiology</li> <li>- Medtronic : pacing</li> </ul>
Widimsky Petr	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Antiischemic agents</li> <li>- Astra Zeneca : Antithrombotic agents</li> <li>- Bayer : Antithrombotic agents</li> <li>- Boehringer-Ingelheim : Antithrombotic agents</li> <li>- Daiichi Sankyo : Antithrombotic agents</li> <li>- Eli Lilly : Antithrombotic agents</li> <li>- The Medicines Company : Antithrombotic agents</li> </ul>



## Guidelines on ACS-NSTE (TF21) - Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Widimsky Petr	Yes	<ul style="list-style-type: none"><li>- Duke University : Antithrombotic agents</li><li>- Abbott : Stents</li><li>- Boston Scientific : Stents</li><li>- Medtronic : Stents</li></ul>



## ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Auricchio Angelo	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Biologics Delivery Systems, Cordis Corporation a Johnson &amp; Johnson company : Biological Therapy</li> <li>- Philips : Cardiac Imaging</li> <li>- Merck : Drugs</li> <li>- Biotronik : Implantable Cardiac Electronic Device</li> <li>- EBR Systems : Implantable Cardiac Electronic Device</li> <li>- Impulse Dynamics : Implantable Cardiac Electronic Device</li> <li>- Medtronic : Implantable Cardiac Electronic Device</li> <li>- Sorin : Implantable Cardiac Electronic Device</li> <li>- St. Jude Medical : Implantable Cardiac Electronic Device</li> <li>- Abbott : Implantable Cardiac Electronic Device</li> </ul>
Baumgartner Helmut	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease</li> <li>- AGA : Devices for catheter treatment of congenital heart defects</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : transcatheter valve implantation</li> </ul>
Bax Jeroen	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Heart.org : Education</li> <li>- Servier : Farma</li> <li>- Astra Zeneca : Farma</li> <li>- GE Healthcare : Imaging</li> <li>- Lantheus : Imaging</li> <li>- Philips : Imaging</li> <li>- St Jude Medical : Pacing</li> </ul>



## ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Bax Jeroen	Yes	<ul style="list-style-type: none"> <li>- Medtronic : Pacing</li> <li>- Impulse Dynamics : Pacing</li> <li>- Biotronik : Pacing</li> <li>- Boston Scientific : Pacing</li> </ul> D - Research funding (departmental or institutional). <ul style="list-style-type: none"> <li>- Servier : Farma</li> <li>- Edwards Lifesciences : Heart Valves</li> <li>- Lantheus : Imaging</li> <li>- GE Healthcare : Imaging</li> <li>- Boston Scientific : Pacing</li> <li>- Medtronic : Pacing</li> <li>- St Jude Medical : Pacing</li> <li>- Biotronik : Pacing</li> </ul>
Ceconi Claudio	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Pharmaceutical
Deaton M Christi	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - St Jude Ltd : Cath lab - speaker X 1 - Daiichi Sankyo : consultant for patient adherence 2009-10 - Eli Lilly : consultant for patient adherence 2009-10 D - Research funding (departmental or institutional). - Novo Nordisk : medicines for diabetes
Fagard Robert	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : perindopril; support for organisation of scientific meeting
Funk-Brentano Christian	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pierre-Fabre : Cardiac Safety of non-cardiovascular products



## ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Funck-Brentano Christian	Yes	<ul style="list-style-type: none"> <li>- Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials.</li> <li>- Johnson &amp; Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials.</li> <li>- Sigma-Tau (Italy) : Cardiac Safety of an antimalarial drug</li> <li>- Santhera (CH) : Cardiac Safety of an antimalarial drug</li> <li>- MMV (CH) : Cardiac Safety of an antimalarial drug</li> <li>- TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis – Cardiac safety</li> <li>- CEPHALON : DSMB in an oncology phase IIb trial</li> <li>- Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Jansen-Cilag : Proton-pump inhibitors and drug interactions with Clopidogrel</li> </ul>
Hasdai David	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Enoxaparin</li> </ul>
Hoes Arno	Yes	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : unrestricted grant for diagnostic kits in suspected cardiovascular disease</li> <li>- Abbott Laboratories : unrestricted grant for diagnostic kits in suspected cardiovascular disease</li> <li>- Roche : unrestricted grant for diagnostic kits in suspected heart failure and acute coronary syndrome</li> </ul>
Knuuti Juhani	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Lantheus Inc : Imaging tracers</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer : Development of imaging agents</li> <li>- GE Healthcare : Development of imaging agents</li> <li>- Lantheus : Development of imaging agents</li> <li>- Novartis : Development of imaging agents</li> <li>- Roche : Drugs for brain diseases</li> </ul>
Kolh Philippe H	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p>



## ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Kolh Philippe H	Yes	<ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Antiarrhythmic agents</li> <li>- Bristol Myers Squibb : Antiplatelet agents</li> <li>- Astra Zeneca : Antiplatelet agents</li> <li>- Regado Biosciences : Antithrombotic agents</li> <li>- Abbott - lecture fees : coronary stents</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Antistaphylococcic vaccine</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Cardiac valves</li> <li>- Medtronic : Cardiac valves</li> <li>- St Jude Medical : Cardiac valves</li> <li>- Siemens Healthcare : Imaging</li> <li>- Johnson &amp; Johnson : Thoracoscopic devices</li> </ul>
McDonagh Theresa	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Vifor International : Ferrinject</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier - speaker fee : Ivabridine</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biotronik - Clinical Trial : CRT</li> </ul>
Poldermans Don	Yes	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Maquette : Balloon pump device</li> <li>- Merck : drugs</li> <li>- Novartis : drugs</li> <li>- Baxter : drugs</li> <li>- Medtronic : Reveal device</li> </ul>



## ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Popescu Bogdan Alexandru	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GE Healthcare : Imaging
Reiner Zeljko	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : anticoagulants - Abbott - lecture fees : antilipemics - Astra Zeneca : antilipemics - Merck Sharp & Dohme : antilipemics - Pfizer : antilipemics
Sechtem Udo	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer Ingelheim : Anticoagulation - Daiichi Sankyo : Antiplatelet therapy - Novartis : Drugs - General Electric : Imaging - Siemens Healthcare : Imaging B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Imaging devices - Johnson & Johnson : Stents
Simes Per Anton	Yes	D - Research funding (departmental or institutional). - Bayer : clinical studies atrial fibrillation investigator fee - Johnson & Johnson : investigator fee, clinical study, atrial fibrillation - MSD : investigator fee clinical studies hyperlipidemia, SCAD - Glaxo Smith Kline : investigator fee, clinical study , SCAD - Servier : investigator fee, clinical study, coronary artery disease - Jansen-Cilag : investigator fee, clinical study, diabetes CVD - Boehringer Ingelheim : investigator fee, clinical study, AF



## ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Torbicki Adam	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulation</li> <li>- Sanofi Aventis : anticoagulation</li> <li>- Pfizer : anticoagulation, pulmonary hypertension</li> <li>- Lilly : pulmonary hypertension</li> <li>- Actelion : pulmonary hypertension</li> <li>- Bayer Healthcare : pulmonary hypertension, anticoagulation</li> </ul>
Vahanian Alec	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Boehringer Ingelheim : Valve prostheses</li> <li>- Siemens Healthcare : Valve prostheses</li> <li>- Valtech : Valve prostheses</li> <li>- Edwards Lifesciences : Valve prostheses</li> <li>- Abbott : Valve prostheses</li> <li>- Medtronic - Advisory Board : Valve prostheses</li> </ul>
Windecker Stephan	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet drug</li> <li>- Eli Lilly : Antiplatelet drug</li> <li>- Abbott : Stent</li> <li>- Biosensors : Stent</li> <li>- Biotronik : Stent</li> <li>- Boston Scientific : Stent</li> <li>- Cordis : Stent</li> <li>- Medtronic : Stent</li> </ul> D - Research funding (departmental or institutional). <ul style="list-style-type: none"> <li>- Medtronic : Stent</li> </ul>



EUROPEAN  
SOCIETY OF  
CARDIOLOGY®

## ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
		- Abbott : Stent - Biosensors : Stent - Cordis : Stent

This table represents the relevant relationships of the above experts with Industry and other entities that were reported to us at the time of publication of the guidelines.